Colombia Patent System

Ecopetrol S.A. (Bogotá, Colombian Stock Exchange listed — Colombia's national oil company; approximately 65% Colombian government-owned; NYSE listed as EC): Ecopetrol is the most significant patent filer in Colombia and the largest company in the country by market capitalization: (1) Ecopetrol's patent activity: Ecopetrol has developed an active innovation and patent strategy particularly focused on: enhanced oil recovery (EOR) technology for Colombia's mature oil fields (primarily in the Llanos Orientales [Eastern Plains] and Magdalena Medio regions); polymer flooding and chemical EOR process patents for Colombia's heavy crude oil reservoirs; steam-assisted gravity drainage (SAGD) and cyclic steam stimulation (CSS) patents for heavy oil in the Llanos (Colombia has significant extra-heavy crude deposits, comparable to Canada's oil sands but accessed differently); natural gas processing patents (Colombia's Cusiana, Cupiagua, and Caño Limón fields); environmental technology patents: biodegradable drilling mud formulations for protecting Colombian Amazon-adjacent ecosystems; produced water treatment process patents; methane capture from pipeline operations; offshore Colombia: Ecopetrol holds exploration rights in the Colombian Caribbean offshore (Sinú-San Jacinto Basin, Guajira Basin) and Pacific offshore — deepwater exploration is early-stage; Ecopetrol's subsea processing and riser technology patents are less advanced than PETROBRAS (Brazil) or PETRONAS (Malaysia) deepwater portfolios; (2) Colombian oil production context: Colombia produces approximately 750,000–800,000 bbl/day — significantly less than Venezuela, Brazil, or Mexico but the 4th or 5th largest producer in Latin America. Colombian crude is primarily Llanos Basin heavy-to-medium crude; the CASTILLA field (Llanos Orientales) is the largest producing field. Ecopetrol's innovation challenge is managing declining mature field production through EOR; (3) Green energy transition: Ecopetrol has announced significant investments in renewable energy, hydrogen, and decarbonization. Colombian renewable energy is developing rapidly (hydropower — Colombia already has approximately 70–75% hydropower electricity generation; solar — Llanos plains solar irradiation is significant; wind — La Guajira peninsula, Colombia's northernmost region, has world-class offshore wind potential [up to 30GW theoretical capacity]). Ecopetrol and other energy companies are filing renewable energy + green hydrogen patents as part of their energy transition strategy; (4) Other Colombian energy IP: ISA (Interconexión Eléctrica S.A. — Colombia's electricity transmission company, also majority Ecopetrol-owned post-2021 acquisition; power grid management, smart grid, energy trading patents); Celsia (Medellín — renewable energy developer; solar + wind patents); XM (Colombian grid operator — smart grid management patent activity).

Colombia's technology sector has grown significantly, driven by Bogotá and Medellín as Latin American startup hubs: (1) Rappi (Bogotá — Latin America's most-funded food delivery and super-app startup; founded 2015 by Simón Borrero, Sebastián Mejía, Felipe Villamarín; valued at approximately $5.25B peak; investors include SoftBank, T. Rowe Price, Andreessen Horowitz, Sequoia): Rappi has developed: delivery logistics optimization algorithms (routing, batching, ETA prediction for on-demand delivery across 9 countries); RappiPay (Colombian digital payment product — NFC payments, QR code payments, financial services); RappiCard (credit card product for underbanked Colombian/LATAM market); supply chain and warehouse management patents; Rappi's IP strategy is primarily trade secret + copyright — patent filing has been limited given the competitive speed of the delivery market, but fintech/payments IP may be filed; (2) Bancolombia Group (Medellín — Colombia's largest private bank; approximately COP 200T in assets; NYSE listed; banking innovation): Bancolombia's fintech and digital banking patents: digital banking platform patents (mobile banking for Colombia's large unbanked population — Bancolombia's Nequi neobank had 13M+ users as of 2023); biometric authentication patents for Colombian banking system (facial recognition, fingerprint authentication at ATMs); real-time payment processing patents for ACH Colombia (Automated Clearing House); SME lending algorithm patents (credit scoring for small businesses using alternative data — utility payment history, mobile money transaction history, GPS-based business location intelligence); (3) Grupo Nutresa (Medellín — one of Latin America's largest food and beverage companies): food formulation patents (chocolate, processed meat, coffee innovation); functional food patents (fiber-enriched products, sugar reduction, probiotic dairy); Grupo Nutresa competes with Nestlé, Unilever, and Kraft Heinz in Colombian and LATAM markets; process efficiency patents for high-volume food manufacturing; (4) Medellín tech ecosystem: Ruta N (Medellín's innovation district — established by Medellín city + EPM + UNE; one of Latin America's most successful urban innovation districts); Area Metropolitana del Valle de Aburrá (AMVA) smart city patents for Medellín's urban mobility and cable car systems (Metrocable); EPM (Empresas Públicas de Medellín — utilities company; smart water management, grid innovation, hydroelectric O&M patents); (5) Colombian agricultural technology: Agrosavia (formerly CORPOICA — Colombia's national agricultural research center): biotechnology patents for tropical crops (cassava, yuca, arracacha, pineapple, cacao); improved rice and soy varieties for Colombian climate; pest management patents; Cenicafé (National Federation of Coffee Growers research center): coffee disease resistance patents (Colombia Castillo variety resistant to coffee leaf rust — Hemileia vastatrix); Colombian cacao fine-flavor variety development; (6) Startups: Habi (Bogotá — real estate data analytics); Kushki (Quito/Bogotá — payment infrastructure for LATAM); Bold (Bogotá — SME payment terminals); Frubana (Bogotá/São Paulo — fresh produce B2B distribution platform).

Yes — Colombia has a 1-year grace period for an applicant's own prior disclosures, established in Article 17 of Andean Community Decision 486 (the Régimen Común sobre Propiedad Industrial, which is the supranational Andean Community law governing patents in Colombia, Ecuador, Peru, and Bolivia): (1) What the grace period covers: disclosures made by the applicant (the patent filer), or by someone who obtained the information from the applicant (for example, through a license, collaboration, or unauthorized disclosure — though authorization affects the analysis), within 12 months before the filing date or before the priority date claimed under the Paris Convention, do NOT count as prior art against the patent application. This means: a Colombian inventor who publishes a paper about their invention, and then files a patent application with SIC (Superintendencia de Industria y Comercio) within 12 months of that publication, is protected — the publication does not destroy the novelty of the patent application; (2) What the grace period does NOT cover: third-party independent disclosures. If a completely independent third party publishes information about the same invention before the Colombian filing date — even if the applicant had no prior contact with that third party — that third-party publication is prior art against the Colombian patent application. The grace period only protects the applicant's own (or derived) disclosures, not independent third-party prior art; (3) Andean Community-wide applicability: the same 1-year own-disclosure grace period under Decision 486 Article 17 applies in all four Andean Community member states — Colombia, Peru, Ecuador, and Bolivia. A disclosure covered by the Article 17 grace period for a Colombian application is equally protected in Peruvian, Ecuadorean, and Bolivian national applications; (4) Comparison with US grace period: the Colombian and US grace periods have very similar structures. US AIA § 102(b)(1)(A) also provides a 12-month own-disclosure grace period: disclosures made by the inventor, joint inventor, or someone who obtained information from them within 12 months before the US filing date do not constitute prior art. The scope of protection is comparable between Colombia and the US for own-disclosure situations; (5) Contrast with EPC countries (no grace period): European Patent Convention member states (Germany, France, Netherlands, Sweden, Spain, Poland, Czech Republic, Hungary, Greece, etc.) have NO general grace period. An EPC inventor who publishes before filing permanently destroys European patent rights. The Colombia/US 1-year own-disclosure grace period does NOT transfer to European patent applications; (6) Best practice recommendation: despite having a 1-year grace period, Colombian patent law best practice is still to file before any public disclosure. The grace period is a legal safety net for situations where disclosure has already occurred — not a recommended filing strategy. Relying on the grace period introduces risk (e.g., if the disclosure timing is disputed, or if unexpected third-party prior art appears in the same field).

Andean Community Decision 486's pharmaceutical patent restrictions are the most commercially significant differentiator between Colombian patent law and the patent systems of the US, EU, Japan, and South Korea. These restrictions reflect a deliberate policy choice by the Andean Community to balance innovation incentives with access to medicines: (1) Legal framework: Decision 486 is supranational Andean Community law — directly applicable and legally superior to Colombian domestic law in IP matters. The Andean Tribunal of Justice (Tribunal de Justicia de la Comunidad Andina, Quito) is the authoritative interpreter. Colombia's SIC (Superintendencia de Industria y Comercio) applies Decision 486 as interpreted by the Andean Tribunal; (2) Non-patentable pharmaceutical subject matter under Decision 486: Article 15 of Decision 486 provides a list of non-patentable subject matter including inventions whose commercial exploitation would be contrary to public order, morality, or the life or health of persons, animals, or plants. Additionally, through Andean Tribunal jurisprudence, the following pharmaceutical patent categories are excluded or severely restricted: (a) New medical uses (second indications) of known compounds: the Andean Tribunal has consistently ruled that if a pharmaceutical compound is known (i.e., has been previously disclosed or patented), a new therapeutic use (second medical indication) for that compound is NOT a patentable invention in the Andean Community. This eliminates 'Swiss-type' use claims (in EPC practice, Swiss-type claims or purpose-limited method claims protect new uses of known compounds); (b) New forms of known substances without enhanced therapeutic efficacy: new physical or chemical forms of known pharmaceutical substances — including new polymorphs (different crystalline structures), new salts, new esters, new hydrates, new solvates, new metabolites — are NOT patentable unless they demonstrate significantly improved therapeutic efficacy compared to the previously known form. This is closely analogous to India's Section 3(d) (Patents Act 1970 as amended) which similarly restricts new form patents without enhanced efficacy; (c) New formulations, combinations, and dosage forms of known drugs: new pharmaceutical formulations (tablets, capsules, modified-release formulations, injectable formulations), new routes of administration, new dosage forms, and fixed-dose combinations of known drugs are NOT patentable without demonstrating enhanced therapeutic efficacy in Colombia; (3) Why this matters commercially — 'evergreening' restriction: in the US and Europe, pharmaceutical companies routinely file secondary patents on: reformulations (extended-release versions, new delivery systems); new salts and polymorphs; fixed-dose combinations (e.g., combining two generically available drugs into a single pill); pediatric formulations; new medical indications; this strategy (sometimes called 'evergreening') extends effective market exclusivity beyond the original 20-year compound patent through clusters of secondary patents. Decision 486 blocks this strategy in Colombia — secondary pharmaceutical patents that would be granted in the US or EU are denied in Colombia; (4) 2016 Colombia compulsory license — lopinavir/ritonavir (Kaletra): Colombia declared lopinavir/ritonavir to be of 'public interest' in 2016 (during a period of significant HIV treatment cost negotiations with AbbVie, the patent holder after acquiring Pharmacyclics/Abbott). This declaration authorized the Colombian government to import and procure generic lopinavir/ritonavir (produced by generic manufacturers, primarily from India) without the consent of the patent holder. The decision generated significant controversy internationally. AbbVie and the US government objected, arguing the Colombian compulsory license undermined innovation incentives; Colombian public health advocates argued the price of branded Kaletra was unaffordable for Colombia's public healthcare system; (5) 2021 Colombia sofosbuvir public interest declaration: similar declaration for sofosbuvir (Sovaldi/Harvoni, Gilead Sciences) for Hepatitis C treatment — enabling generic access.

Ecopetrol S.A. is the most active patent filer in Colombia and the most significant IP-generating company in the Colombian economy, reflecting both the oil company's central role in the Colombian economy and its strategic investment in R&D: (1) Corporate overview: Ecopetrol S.A. (Empresa Colombiana de Petróleos — Colombian Petroleum Company) is Colombia's national oil company, listed on the Colombian Stock Exchange (BVC) and NYSE (EC). The Colombian government directly holds approximately 88% of Ecopetrol's shares. Ecopetrol had revenues of approximately COP 91 trillion (approximately $23B USD) in 2022. Ecopetrol controls approximately 50% of Colombia's proven oil reserves and is the country's largest producer (~720,000 bbl/day in recent years); (2) R&D and IP investment: Ecopetrol has made significant investments in R&D through: ICP (Instituto Colombiano del Petróleo / Colombian Petroleum Institute, Bucaramanga, Santander) — Ecopetrol's primary research center; Centro de Innovación y Tecnología (CIT, Bogotá) — corporate innovation hub; the company has developed a culture of filing patents on its innovations, which is unusual for a Latin American state-owned oil company (many state oil companies rely primarily on technology licensing from international service companies rather than developing indigenous IP); (3) Key patent areas: Enhanced Oil Recovery (EOR): Ecopetrol's mature Llanos Orientales fields (La Cira-Infantas — one of the world's oldest continuously operating oil fields, discovered 1918; Campo Castilla; Chichimene) are declining in production from primary recovery. EOR patents include: polymer flooding technology for heavy crude (SARAUSA synthetic polymer formulations for Colombia's specific reservoir conditions); microbial EOR (MEOR — using indigenous microorganisms to improve recovery); in-situ combustion processes for Llanos heavy crudes; CO2 injection EOR; Environmental/clean technology patents: biodegradable drilling mud formulations (Colombia drills near Amazon-adjacent protected areas — requires environmental protection); produced water treatment (separating water from crude production); methane capture from pipeline leaks and production operations; unconventional resources: Ecopetrol has Colombia's most active unconventional oil and gas (shale gas, tight oil) research program, though Colombia's political environment has created significant uncertainty around hydraulic fracturing (fracking moratorium and regulatory debates); horizontal drilling and fracturing adaptation patents for Colombian formations; Digital and AI: Ecopetrol Innova Program — digital transformation through machine learning for: production optimization (predictive maintenance for wells, compressors, pipelines); seismic interpretation AI for Colombian geological structures; drone and robotics for pipeline inspection; (4) Global patent filing strategy: Ecopetrol files patents via PCT (obtaining global coverage through national phase filings), USPTO (for US commercial significance), and EPO (for European partners). SIC (Colombian national filings) are used for inventions primarily of domestic relevance; (5) Acquisitions: Ecopetrol acquired ISA (Interconexión Eléctrica S.A. — electricity transmission infrastructure company) in 2021 for approximately COP 13.7 trillion (~$3.5B), adding ISA's smart grid and power transmission IP to the Ecopetrol group patent portfolio.

Colombia is one of the world's most biodiverse countries — approximately 10% of all plant species on Earth are found in Colombia, and the country contains portions of the Amazon, Andes, Pacific, Caribbean coastal, and Llanos ecosystems. This extraordinary biodiversity creates specific IP obligations that are unique to Colombian (and Andean Community) patent law: (1) Andean Community Decision 391 — Common Regime on Access to Genetic Resources: Decision 391 establishes a mandatory access and benefit-sharing (ABS) framework for genetic resources in Andean Community member states including Colombia. Under Decision 391: any access to genetic resources in Colombia (plants, animals, microorganisms, or genetic material derived from them) for commercial or research purposes requires: a prior informed consent (PIC) agreement with the competent national authority (in Colombia: ANLA — Autoridad Nacional de Licencias Ambientales [National Environmental Licensing Authority] and the Ministry of Environment); an access contract specifying the scope of access, purpose, and benefit-sharing obligations; a fair and equitable sharing of benefits arising from the commercial use of the genetic resources with Colombia and, where relevant, with the indigenous or local community whose traditional knowledge was associated with the resource; (2) Patent applications and genetic resource disclosure: if a patent application in Colombia relates to an invention involving a genetic resource or associated traditional knowledge from Colombia or another Andean Community member state, the applicant must disclose: the country of origin of the genetic resource; evidence of prior informed consent (the access contract with ANLA/Ministry of Environment); compliance with Decision 391; if the applicant cannot demonstrate proper access authorization, the patent application can be refused or the granted patent can be nullified; (3) Practical impact: Colombia's genetic resource requirements are most significant for: pharmaceutical and biotechnology patents based on biological molecules from Colombian plants or microorganisms; agricultural biotechnology patents based on genetic material from Colombian crop varieties or wild relatives; nutraceutical or cosmetic patents based on plant extracts from Colombian biodiversity; research from international institutions (universities, pharmaceutical companies) accessing Colombian biological material; (4) The Nagoya Protocol: the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization (adopted 2010, in force 2014) is an international CBD (Convention on Biological Diversity) Protocol governing ABS at a global level. Colombia has ratified the Nagoya Protocol. The US has NOT ratified the Nagoya Protocol (or the CBD), which creates a compliance asymmetry — US companies accessing Colombian genetic resources must comply with Colombia's Decision 391 requirements for Colombian patent protection, but Colombia cannot enforce Nagoya Protocol benefit-sharing obligations in US courts for US patents; (5) Indigenous traditional knowledge protection: Colombia has constitutional protections for indigenous peoples' cultural rights (Constitution 1991, Article 63 — collective property of indigenous reservations). Traditional knowledge of indigenous communities (Amazonian, Andean, Pacific coastal) is subject to specific protections that interact with the patent system through the disclosure-of-origin requirement. Patents on inventions derived from indigenous traditional knowledge without consent and benefit-sharing are considered biopiracy under Colombian constitutional and Andean Community law.

Colombia's utility model (modelo de utilidad) is established by Andean Community Decision 486, Articles 81–85, and provides a form of IP protection for practical, functional inventions with a shorter examination process and a lower inventive step requirement: (1) Term: 10 years from the filing date — non-renewable and non-extendable in Colombia under Decision 486. CONTRAST: German Gebrauchsmuster (utility model) = 10 years; Czech vzor užitný = 10 years maximum; Malaysian utility innovation = 14 years maximum; Chile and US = no utility model; (2) Scope — what is protected: Colombian utility models protect: tools, implements, devices, and PRODUCTS (physical, three-dimensional objects); APPARATUS and UTENSILS; the utility model must be new (relative novelty, same standard as full patent under Decision 486); it must be industrially applicable; it must have utility (be useful and functional). What Colombian utility model CANNOT protect: processes and methods — a manufacturing process, chemical synthesis process, or industrial method cannot be the subject of a utility model application; biological material — microorganisms, plants, animals, and genetic material; chemical substances and compositions — pure chemicals and pharmaceutical compounds cannot be a utility model; (3) Inventive step — lower bar: the utility model requires only 'actividad inventiva menor' (a lesser inventive step) compared to the full patent's inventive step requirement. The Colombian SIC applies a more lenient obviousness analysis for utility model applications — an incremental improvement that might be obvious for a full patent may still qualify for utility model protection. This allows smaller companies and individual inventors to obtain protection for practical device improvements that represent genuine innovation in their sector without meeting the higher non-obviousness bar of a full patent; (4) Examination: Colombia's SIC examines utility model applications substantively (unlike Malaysia's registered utility innovation which skips substantive examination, or South Africa's unexamined patent system). The SIC examination for utility models is substantive but typically faster than full patent examination; (5) Conversion: a pending patent application can be converted to a utility model application in Colombia; (6) Enforcement: utility model enforcement in Colombia follows the same legal process as patent enforcement — Colombian civil or commercial courts (with specialized IP chambers in Bogotá); preliminary injunctions available; damages based on lost profits or reasonable royalty; (7) US comparison: the US has no utility model or petty patent system. A Colombian utility model invention in the 'product' category (device, tool, apparatus) would need to go through full US utility patent examination at the USPTO — the same 20-year patent protection applies but with full non-obviousness scrutiny under § 103 and KSR International v. Teleflex (2007) analysis.